title: Changing the adenovirus fiber for retaining gene delivery efficacy in the presence of neutralizing antibodies.
abstract: Prior infection has primed most adult humans for a rapid neutralizing antibody (NAb) response when re-exposed to adenovirus. NAb induction can severely limit the efficacy of systemic re-administration of adenoviral gene therapy. We hypothesized that changing the fiber knob could overcome NAb. Immune-competent mice were exposed to serotype 5 adenovirus (Ad5)(GL), Ad5/3luc1, Ad5lucRGD or Ad5pK7(GL). Mice immunized with Ad5(GL) featured reduced intravenous Ad5(GL) gene transfer to most organs, including the liver, lung and spleen. Ad5(GL) gene transfer was affected much less by exposure to capsid-modified viruses. Anti-Ad5(GL) NAb blocked intravenous Ad5(GL) gene transfer to orthotopic lung cancer xenografts, whereas capsid-modified viruses were not affected. When gene transfer to fresh cancer and normal lung explants was analyzed, we found that capsid-modified viruses allowed effective gene delivery to tumors in the presence of anti-Ad5(GL) NAb, whereas Ad5(GL) was blocked. In contrast, crossblocking by NAbs induced by different viruses affected gene delivery to normal human lung explants, suggesting the importance of non-fiber-knob-mediated infection mechanisms. We conclude that changing the adenovirus fiber knob is sufficient to allow a relative degree of escape from preexisting NAb. If confirmed in trials, this approach might improve the efficacy of re-administration of adenoviral gene therapy to humans.
authors.affiliation: Molecular Cancer Biology Program and Transplantation Laboratory, University of Helsinki, Helsinki, Finland.
authors.forename: M
authors.initials: M
authors.lastname: Särkioja
authors.forename: S
authors.initials: S
authors.lastname: Pesonen
authors.forename: M
authors.initials: M
authors.lastname: Raki
authors.forename: T
authors.initials: T
authors.lastname: Hakkarainen
authors.forename: J
authors.initials: J
authors.lastname: Salo
authors.forename: M T
authors.initials: MT
authors.lastname: Ahonen
authors.forename: A
authors.initials: A
authors.lastname: Kanerva
authors.forename: A
authors.initials: A
authors.lastname: Hemminki
mesh_terms: D000256:Adenoviridae / Q000235:genetics*; D000818:Animals; D000914:Antibodies, Viral / Q000276:immunology; D000956:Antigens, Viral / Q000235:genetics / Q000276:immunology; D036022:Capsid Proteins / Q000235:genetics; D002289:Carcinoma, Non-Small-Cell Lung / Q000628:therapy; D005818:Genetic Engineering; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors / Q000008:administration & dosage / Q000235:genetics*; D006801:Humans; D008168:Lung / Q000276:immunology / Q000821:virology; D008175:Lung Neoplasms / Q000276:immunology* / Q000628:therapy*; D051379:Mice; D008813:Mice, Inbred ICR; D008819:Mice, Nude; D014161:Transduction, Genetic; D023041:Xenograft Model Antitumor Assays
chemical_list: D000914:Antibodies, Viral; D000956:Antigens, Viral; D036022:Capsid Proteins; C018315:hexon capsid protein, Adenovirus